{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001035","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.281205+00:00","generated_at":"2026-06-05T07:56:46.748903+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cassava Sciences reports FY2023 net loss of $97.2M; Phase 3 topline data expected year-end 2024","bullets":["Net loss $97.2M ($2.32/share) vs $76.2M ($1.90) in 2022; R&D expenses $89.4M.","Cash and equivalents $121.1M at 12/31/23; $21.8M raised in 2024 from warrant exercises.","Over 555 patients completed Phase 3 studies; topline data for 52-week trial expected year-end 2024.","Internal investigation found no evidence substantiating allegations of research misconduct.","Net cash used in operations $82M in 2023; expected $35-45M in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001035","json":"https://secwatch.observer/filing/0001171843-24-001035.json","markdown":"https://secwatch.observer/filing/0001171843-24-001035.md","text":"https://secwatch.observer/filing/0001171843-24-001035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324001035/0001171843-24-001035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324001035/f8k_022824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:56:46.748903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31a43c2411038d469d6be2c240bcdc91917c8c70","claim":"FILANA THERAPEUTICS, INC. reported full year ended December 31, 2023 results: net income net loss of $97.2 million, EPS loss of $2.32 per share.","evidence_excerpt":"Net loss for full year 2023 was $97.2 million, or $2.32 per share, compared to a net loss of $76.2 million, or $1.90 per share, in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324001035/0001171843-24-001035-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Net income","value":"net loss of $97.2 million"},{"label":"EPS","value":"loss of $2.32 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}